Skip to main content

DataMeds AI, Inc.

corporate_fare Company Profile

DataMeds AI, Inc.

MEDS·NASDAQ·Trade & Services·CIK 0002030763

DataMeds AI, Inc. is a holding company incorporated in 2022, focused on pharmaceuticals and healthcare services. The company aims to create a micro health ecosystem by integrating a pharmacy, wholesale operations, and a technology division that offers a novel platform for hub and clinical services. DataMeds AI, Inc. seeks to improve patient lives and provide solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its patient-centric approach and innovative healthcare applications are designed to shift pharmaceutical care to revolve around the patient across various therapeutic conditions. The company offers a full spectrum of integrated solutions by leveraging its business segments to address access, care coordination, dispensing, delivery, and clinical management of pharmaceutical products, from "specialty-lite" to general maintenance conditions. DataMeds AI, Inc. operates through two wholly owned subsidiaries: Wood Sage LLC and Wellgistics, LLC, and two indirect subsidiaries: Alliance Pharma Solutions LLC d/b/a DelivMeds (now Wellgistics Tech & Hub, LLC) and Community Specialty Pharmacy, LLC (now Wellgistics Pharmacy). In January 2023, the company entered into a Membership Interest Purchase Agreement for the acquisition of Wood Sage, which was completed on June 16, 2024. The acquisition involved paying Mr. Panchal approximately $400,000 in common stock issued at a 20% discount. Wood Sage, a Florida limited liability company formed on June 27, 2014, had no operations to date. In August 2023, Wood Sage acquired 100% of the outstanding membership interests of DelivMeds and Wellgistics Pharmacy.

DataMeds AI, Inc. (NASDAQ:MEDS) is a publicly traded company in the Trade & Services sector. Wiseek has independently scored 24 items for MEDS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for MEDS spans PRE 14C, 8-K, 10-Q, S-1/A.

Recent high-impact activity:

  • DataMeds Wins Consent for Axe Compute Note Conversion With Full-Ratchet Reset
  • DataMeds AI Launches $10.0M At-The-Market Program With Dawson James
  • DataMeds AI Q3: $10.5M Net Income on Debt-Extinguishment Gain, Going Concern Persists
  • DataMEDS AI Swings to $10.5M Q3 Profit on Debt Extinguishment; Revenue Up 50% Sequentially
  • Q3 Revenue Jumps 50% Sequentially as DataMEDS Swings to $10.5M Operating Profit

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$23.34M
Net Income
-$101.27M
Diluted EPS
-$1.43
Op. Cash Flow
-$10.86M
Gross Profit
-$6.43M
Operating Income
-$93.75M
Cash & Equivalents
$42.57K
Total Debt
$23.49M
Debt / Equity
-1.89×
Net Margin
-433.9%
Shares Outstanding
101.31M sh
Source: 10-K · filed 2026-04-24 · accession 0001493152-26-018958

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 371,417 shares in MEDS as of the October 30, 2026 settlement, a 22.0% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 55.9% of MEDS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)371,417 shares as of October 30, 2026
Change vs prior period▼ 22.0%
Days to cover1.00 at avg daily volume of 713,418
Daily short volume (FINRA facilities)55.9% of 44,440,638 shares on November 20, 2026
5-day average short volume55.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for MEDS, detected from its recent SEC filings · based on capital-structure filings through 2026-11-17.

1 recent capital raiseATM program1 shelf registration

ATM Prospectus Supplement Filed · No Shares Sold Yet

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with M →
$1.55 +15.67% today
52-week range · as of 2026-11-16 $0.5525 – $35.5
Market cap
$7.66M
Volume
94.2M (17.4× avg)
3-mo avg 5.4M
Live data · 2026-11-22 10:48 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MEDS - Latest Insights

MEDS
Nov 16, 2026, 8:42 AM EST
Filing Type: PRE 14C
Importance Score:
8
Price at Filing: $0.7001
Real-time Price: $1.55 info
Change: +$0.8499 (+121%) info
Market Cap: $7.662M info
MEDS
Nov 16, 2026, 6:01 AM EST
Filing Type: 8-K
Importance Score:
7
Updated Nov 16, 6:24 AM ET — The ATM prospectus supplement sets the offering at up to $10,003,649, or up to 13,518,445 shares at $0.74, with Dawson James paid a 3.0% co…
Price at Filing: $0.710
Real-time Price: $1.55 info
Change: +$0.840 (+118%) info
Market Cap: $7.662M info
MEDS
Nov 13, 2026, 5:12 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.7251
Real-time Price: $1.55 info
Change: +$0.8249 (+114%) info
Market Cap: $7.662M info
MEDS
Nov 13, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7499
Real-time Price: $1.55 info
Change: +$0.8001 (+107%) info
Market Cap: $7.662M info
MEDS
Nov 13, 2026, 10:20 AM EST
Source: ACCESS Newswire
Importance Score:
8
Price at Filing: $0.8795
Real-time Price: $1.55 info
Change: +$0.6705 (+76%) info
Market Cap: $7.662M info
MEDS
Nov 10, 2026, 4:30 PM EST
Filing Type: S-1/A
Importance Score:
8
Price at Filing: $0.9215
Real-time Price: $1.55 info
Change: +$0.6285 (+68%) info
Market Cap: $7.662M info
MEDS
Nov 05, 2026, 6:08 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.51
Real-time Price: $1.55 info
Change: +$0.040 (+3%) info
Market Cap: $7.662M info
MEDS
Nov 03, 2026, 6:18 PM EST
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $1.70
Real-time Price: $1.55 info
Change: -$0.150 (-9%) info
Market Cap: $7.662M info
MEDS
Oct 26, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.14
Real-time Price: $1.55 info
Change: -$0.590 (-28%) info
Market Cap: $7.662M info
MEDS
Oct 16, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Updated Oct 16, 5:23 PM ET — DataMeds will pay REBOOT $50,000 and at least an estimated $100,000 for reconfiguration under the license.
Price at Filing: $2.66
Real-time Price: $1.55 info
Change: -$1.11 (-42%) info
Market Cap: $7.662M info
MEDS
Oct 13, 2026, 5:27 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.01
Real-time Price: $1.55 info
Change: -$1.46 (-49%) info
Market Cap: $7.662M info
MEDS
Oct 13, 2026, 12:47 PM EDT
Filing Type: PRE 14C
Importance Score:
8
Price at Filing: $3.10
Real-time Price: $1.55 info
Change: -$1.55 (-50%) info
Market Cap: $7.662M info
MEDS
Oct 12, 2026, 6:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.15
Real-time Price: $1.55 info
Change: -$1.60 (-51%) info
Market Cap: $7.662M info
MEDS
Oct 09, 2026, 5:20 PM EDT
Filing Type: S-1/A
Importance Score:
8
Price at Filing: $3.02
Real-time Price: $1.55 info
Change: -$1.47 (-49%) info
Market Cap: $7.662M info
MEDS
Oct 01, 2026, 6:00 AM EDT
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $3.49
Real-time Price: $1.55 info
Change: -$1.94 (-56%) info
Market Cap: $7.662M info
MEDS
Sep 18, 2026, 6:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $4.25
Real-time Price: $1.55 info
Change: -$2.70 (-64%) info
Market Cap: $7.662M info
MEDS
Sep 17, 2026, 5:23 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.88
Real-time Price: $1.55 info
Change: -$3.33 (-68%) info
Market Cap: $7.662M info
MEDS
Sep 16, 2026, 5:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.12
Real-time Price: $1.55 info
Change: -$4.57 (-75%) info
Market Cap: $7.662M info
MEDS
Sep 15, 2026, 4:05 PM EDT
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $1.62
Real-time Price: $1.55 info
Change: -$0.070 (-4%) info
Market Cap: $7.662M info
MEDS
Aug 31, 2026, 5:27 PM EDT
Filing Type: PRE 14C
Importance Score:
8
Price at Filing: $0.9909
Real-time Price: $1.55 info
Change: +$0.5591 (+56%) info
Market Cap: $7.662M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets